VGR
VECTOR GROUP LTD
No data for this timeframe.
Vol
Inst. Holders1 funds
Inst. Value$4.1M
Inst. Activity0 buys / 14 sells
SEC Reports1
Recent Activity
Feb 28, 2026
SEC
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and Schwab — fully exited their positions in
INST-CLUSTER — Impact 7/10
Inst.
MORGAN STANLEY — EXIT
0 shares ($0.00)
Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Analyst Ratings
2Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BARCLAYS PLC | $4.1M | — |
1 institutional holders with $4.1M total value (276,687 shares) as of 2025-Q3. Top holders: BARCLAYS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | 276,687 | $4.1M | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | EXIT | 1,374,282 | 0 | -100.0% | $0.00 | 2024-Q4 |
| STATE STREET CORP | EXIT | 5,008,394 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 1,998,525 | 0 | -100.0% | $0.00 | 2024-Q4 |
| Invesco Ltd. | EXIT | 905,091 | 0 | -100.0% | $0.00 | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 9,043,222 | 0 | -100.0% | $0.00 | 2024-Q4 |
| D. E. Shaw & Co., Inc. | EXIT | 1,525,644 | 0 | -100.0% | $0.00 | 2024-Q4 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | 3,066,964 | 0 | -100.0% | $0.00 | 2024-Q4 |
| VANGUARD GROUP INC | EXIT | 16,217,821 | 0 | -100.0% | $0.00 | 2024-Q4 |
| BlackRock, Inc. | EXIT | 21,763,647 | 0 | -100.0% | $0.00 | 2024-Q4 |
| FIL Ltd | EXIT | 2,584,034 | 0 | -100.0% | $0.00 | 2024-Q4 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | EXIT | 856,409 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | EXIT | 1,124,589 | 0 | -100.0% | $0.00 | 2024-Q4 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | EXIT | 854,332 | 0 | -100.0% | $0.00 | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | EXIT | 930,215 | 0 | -100.0% | $0.00 | 2024-Q4 |
| FIL Ltd | NEW | — | 2,584,034 | — | $38.6M | 2024-Q3 |
| D. E. Shaw & Co., Inc. | ADD | 1,167,955 | 1,525,644 | +30.6% | $22.8M | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 171,526 | 930,215 | +442.3% | $13.9M | 2024-Q3 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 395,931 | 856,409 | +116.3% | $12.8M | 2024-Q3 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | NEW | — | 854,332 | — | $12.7M | 2024-Q3 |
| AMERIPRISE FINANCIAL INC | TRIM | 594,327 | 389,699 | -34.4% | $5.8M | 2024-Q3 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 713,851 | 235,322 | -67.0% | $3.5M | 2024-Q3 |
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | 41,095 | 201,164 | +389.5% | $3.0M | 2024-Q3 |
| CITIGROUP INC | ADD | 118,373 | 192,008 | +62.2% | $2.9M | 2024-Q3 |
| ALPS ADVISORS INC | ADD | 105,477 | 191,948 | +82.0% | $2.9M | 2024-Q3 |
| Verition Fund Management LLC | DOUBLED | 64,890 | 186,442 | +187.3% | $2.8M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 83% buy across 6 analysts — 2 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jan 1, 2025 | 2 | 3 | 1 | 0 | 0 | 83% | |
| Dec 1, 2024 | 2 | 3 | 1 | 0 | 0 | 83% | |
| Nov 1, 2024 | 2 | 3 | 1 | 0 | 0 | 83% | |
| Oct 1, 2024 | 2 | 3 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.